Choosing the Course of Passion: Brooke Boyarsky Pratt at knownwell Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Revenue Model: Knownwell operates on a hybrid model, combining insurance-reimbursable medical services with a direct-to-consumer (DTC) subscription component ($99/month for access to specialized care, community, and digital tools).
Market Sizing: The obesity and metabolic health market in the US encompasses over 100 million adults.
Funding: Pratt secured seed funding, though the case notes the pressure to demonstrate unit economics that justify a Series A valuation (Exhibit 3).

Operational Facts

Service Delivery: Knownwell provides comprehensive metabolic health care, including nutrition counseling, behavioral health, and medical weight management (GLP-1s where clinically indicated).
Geography: Initially launched in Massachusetts (paragraph 4); expansion plans focus on state-by-state licensure requirements.
Team: Small, cross-functional team combining clinical expertise (MDs, RDs) with consumer-tech talent.

Stakeholder Positions

Brooke Boyarsky Pratt: Founder/CEO, driven by personal mission, currently balancing the tension between mission-driven care and rapid scale.
Investors: Focused on speed to market and customer acquisition cost (CAC) versus lifetime value (LTV) ratios.
Patients: Seeking sustainable, long-term weight management alternatives to traditional, fragmented medical systems.

Information Gaps

Churn Data: Retention rates for the $99/month subscription are not explicitly provided.
Insurance Reimbursement Ratios: The exact split between insurance revenue and subscription revenue is not quantified.
GLP-1 Supply Chain: The impact of GLP-1 shortages on patient acquisition and retention is mentioned as a risk but not quantified.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How does Knownwell scale its specialized metabolic health model to achieve venture-scale growth without compromising clinical outcomes or diluting its subscription-based unit economics?

Structural Analysis

Value Chain: Knownwell controls the full stack, from physician consultation to digital support. This is high-cost but necessary for clinical differentiation.
Competitive Landscape: Direct competition from high-volume telehealth players (e.g., Ro, WeightWatchers) vs. specialized clinics. Knownwell occupies a premium, high-touch niche.

Strategic Options

Option 1: Aggressive Geographic Expansion. Rapidly secure medical licenses in 10+ states. Trade-off: High burn rate, risk of operational fragmentation.
Option 2: B2B/Employer Partnerships. Pivot to selling the platform as a corporate wellness benefit. Trade-off: Lower margins, longer sales cycles, but higher LTV and lower CAC.
Option 3: Digital-First Optimization. Focus on refining the digital product to reduce the need for synchronous physician time. Trade-off: May reduce clinical efficacy and brand premium.

Preliminary Recommendation

Pursue Option 2 (B2B Partnerships). The current DTC model is susceptible to high customer acquisition costs as the market matures. Partnering with self-insured employers provides a stable, recurring revenue stream and lowers the cost of acquisition per patient.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Clinical Standardization: Codify the care protocol to ensure consistent quality across new clinician hires.
B2B Sales Pilot: Secure two mid-sized self-insured employers in the current licensure state to validate the B2B conversion funnel.
Platform Integration: Build the administrative portal for employers to track anonymized population health metrics.

Key Constraints

Regulatory Compliance: State-level medical board requirements limit the speed of cross-state physician deployment.
Clinical Capacity: Availability of specialized clinicians who align with Knownwell’s high-touch philosophy.

Risk-Adjusted Implementation

Prioritize hiring a dedicated B2B sales lead with existing relationships in the benefits consulting space. Build a three-month buffer into the pilot phase to account for the complexity of integrating with employer health insurance plans.

4. Executive Review and BLUF (Executive Critic)

BLUF

Knownwell must pivot to B2B partnerships immediately. The DTC model is a trap; customer acquisition costs for metabolic health are rising, and the $99/month price point is insufficient to cover the high-touch clinical model at scale. By targeting self-insured employers, the company gains access to captive patient populations, significantly reducing CAC and stabilizing cash flow. The current focus on rapid state-by-state DTC expansion is a capital-intensive distraction that will exhaust the remaining runway before the company achieves the requisite density to be profitable. Focus the team on securing three enterprise contracts by year-end. This is the only path to the growth metrics required for a successful Series A.

Dangerous Assumption

The assumption that the DTC subscription model can be scaled efficiently while maintaining the current high-touch clinical standard. It cannot; clinical labor costs will outpace subscription revenue growth.

Unaddressed Risks

GLP-1 Dependency: If supply constraints worsen or insurance coverage for GLP-1s shifts, the core value proposition is undermined.
Platform Complexity: Managing enterprise-level data privacy (HIPAA) while providing actionable insights to employers creates a massive technical and legal overhead.

Unconsidered Alternative

Out-licensing the clinical protocol to existing regional health systems. This allows Knownwell to capture revenue without the burden of building the physical or telehealth infrastructure itself.